Amgen Epogen continues strong growth
Executive Summary
Epoetin alfa sales increased 30% to $395 mil. during the first quarter, Amgen reported. The company "continues to expect Epogen percentage growth to be in the low 20s for the full year." Neupogen (filgrastim) sales increased 10% to $287 mil., and Amgen is forecasting full-year growth "in the high single digits." Infergen (interferon alfacon-1) posted $6 mil. in sales for the quarter